Adagrasib
Krazati · KRAS G12C inhibitor
Creatinine rise; emerging data.
BCR-ABL1 tyrosine kinase inhibitor (3rd generation)
Olverembatinib (HQP1351) · BCR-ABL TKI
BCR-ABL1 tyrosine kinase inhibitor (3rd generation) · approved 2021 · 5 citations
Describes how this page is sourced, not how dangerous the drug is. Thinly sourced means fewer of the sourcing signals are met — not that the agent is kidney-safe. A rule-based summary, not a formal certainty appraisal.
Potent T315I-active TKI with a largely renal-sparing profile
Atlas fields gathered in one place, each linked to the section with its full text and sources. Educational, not medical advice.
Signature lesion
Renal-specific data are sparse. In the Chinese phase 1/2 program (n=165) proteinuria was among the common treatment-related adverse events, though grade and exact rate were not separately quantified; clinically significant AKI was not a prominent signal. Direct nephrotoxicity appears low overall.Source: Proteinuria listed among common treatment-related AEs in the phase 1/2 trial (Jiang Q et al., J Hematol Oncol 2022; PMID 35982483).
Onset is variable, with proteinuria and hypertension from multi-kinase TKIs typically emerging over weeks to months of therapy.
Distilled from: “Variable; proteinuria and hypertension, when they occur with multi-kinase TKIs, typically emerge over weeks to months of therapy.”
This agent's kidney lesions ordered by prominence — the #1 signature lesion first, then secondary and rare patterns. Cited incidence is shown where a citable figure exists; otherwise the tier stands qualitatively.
Proteinuria is listed among the common treatment-related adverse events in the pivotal phase 1/2 program (165 TKI-resistant CML patients); podocyte/glomerular proteinuria is the characteristic renal signal of this third-generation BCR-ABL1 TKI (no population incidence denominator reported). PMID 35982483 (opens PubMed in a new tab)
Raised blood pressure — archetypally on-target loss of endothelial nitric oxide from VEGF-pathway blockade, studied as a pharmacodynamic marker of drug exposure. Other agents raise it too: vascular effects of BCR-ABL, BTK and RET inhibitors and of copanlisib; abiraterone's mineralocorticoid excess; androgen suppression or blockade.
Renal hypoperfusion from capillary leak and cytokine storm — IL-2 and CAR-T cytokine release syndrome.
The great mimic — a rise in creatinine from blocked tubular secretion (OCT2/MATE), NOT true injury. The GFR is intact; confirm with cystatin C before stopping effective therapy.
Tap a signature to trace where it strikes the nephron.
Glomerular Injury / Proteinuria strikes: Glomerulus.
Glomerular Injury / Proteinuria
Damage to the filtration barrier — podocyte injury, FSGS and protein leak from VEGF and mTOR blockade.
Orally bioavailable third-generation BCR-ABL1 tyrosine kinase inhibitor that potently inhibits native BCR-ABL1 and a broad spectrum of resistance mutants, including the gatekeeper T315I mutation and compound mutations. It binds the ATP pocket of the ABL1 kinase domain, halting constitutive kinase signaling that drives Philadelphia-chromosome-positive CML and ALL. Like ponatinib, it has multi-kinase activity (including against VEGFR/PDGFR-family and KIT), which underlies both its broad efficacy and its off-target vascular and podocyte-relevant effects.
Class-level context for the major non-renal toxicities of the BCR-ABL1 tyrosine kinase inhibitor (3rd generation) class.
Vascular
Hypertension, VTE/ATE, bleeding, aneurysm
Pulmonary
Pneumonitis, ILD, effusions, hypertension
Cardiac
Cardiomyopathy, QT, ischemia, myocarditis
4 primary references — trials, cohorts, mechanism, and reviews. Single-patient case reports are listed separately below, graded by strength. Citation metadata via PubMed / NLM.
Primary (non–case-report) references per year — a proxy for how actively the agent's renal literature is accruing. Recent years are highlighted. Reflects curation depth, not a systematic bibliometric count.
Single-patient and small-series reports, graded by evidentiary strength — A Strong (biopsy-proven plus a series and/or positive rechallenge), B Moderate, and C Limited (a single clinically-diagnosed case). Strongest first. Grades are inferred automatically from each report's abstract and journal — a heuristic ranking aid, not a formal quality appraisal.
Everything below is FAERS — adverse events someone chose to report, about 33 of them for this agent. Nobody counts the patients who were fine, so none of these numbers is an incidence, a risk, or a rate: they describe what gets reported, shaped by a drug's fame, its indication, and who was watching. How these numbers work.
33 total FAERS reports is below the 50 this atlas requires before quoting an odds ratio, so report counts are shown instead of RORs and none of these counts as a signal. A phenotype missing below was queried and never cleared even the nominal CI bar, except Prerenal / Hemodynamic AKI, Pseudo-AKI, Renal Cysts, Chronic Interstitial Nephropathy — outside the clinician-reviewed MedDRA term map, never queried — and ATN and AIN, queried but biopsy-bound: real cases are filed as generic “acute kidney injury”, so their absence is not a negative. As of 2026-11-15.
What reporting says about this profile's documented lesions
33 reports is below the 50 this atlas requires before quoting a percentage, so the counts are shown instead of shares.
Reported with a death outcome
too few reports to express as a share
Reported with hospitalization
too few reports to express as a share
Reports per year
Reports received per year, 2015–2026 · most recent year is partial.
Bars rank systems by summed reaction-term mentions (a report counts once per term it names) — an ordinal “more vs less reported” cue, not a tally of distinct reports. Renal & urinary first. As of 2026-11-15.
Each recommendation below is this atlas's faithful summary of the source, not a quotation from it — follow the PubMed link for the wording the society published. Summaries may be superseded; consult the current full text and individualize to the patient.
General onco-nephrology references
Where Olverembatinib sits in nephrotoxicity space — each dot is an anti-cancer agent, positioned so neighbors share a kidney-injury phenotype. Its 6 closest are filled and lead to a numbered marker, matching the numbered cards below.
Krazati · KRAS G12C inhibitor
Creatinine rise; emerging data.
Scemblix · BCR-ABL STAMP inhibitor
Hypertension and pancreatitis; allosteric BCR-ABL inhibitor.
Sutent · VEGFR TKI
VEGFR-TKI; hypertension and proteinuria, TMA reported.
Danyelza · Anti-GD2 antibody
Anti-GD2 antibody; infusion-related hypertension and prerenal AKI.
Alunbrig · ALK TKI
Creatinine elevation; usually benign.
Lorbrena · ALK TKI
Edema and metabolic effects.
Nearest agents by kidney-injury phenotype (shared injuries, nephron target, severity, class) — a similarity approximation, not a claim of shared drug identity or mechanism.
Same-class agents ordered by their documented kidney-injury profile — atlas severity, an acute-kidney-injury FAERS signal, and how many injury types each is documented to cause. Agents nearer the top carry the lighter documented renal profile. Agents sharing a number are tied on all three. An agent marked FAERS n/a has too few reports to test, so its place rests on severity and injury breadth alone.
A comparison of documented kidney-injury data within one drug class — not a substitution recommendation. Efficacy, indication, and non-renal toxicity differ between these agents and are out of scope here. Educational only, not medical advice.